Akoya Biosciences, Inc.
AKYA
$1.16
-$0.06-4.92%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 21.34M | 18.81M | 23.16M | 18.35M | 26.49M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 21.34M | 18.81M | 23.16M | 18.35M | 26.49M |
| Cost of Revenue | 6.96M | 7.09M | 9.78M | 9.97M | 9.87M |
| Gross Profit | 14.39M | 11.72M | 13.39M | 8.38M | 16.62M |
| SG&A Expenses | 15.69M | 14.67M | 19.09M | 19.86M | 20.08M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.07M | 26.24M | 34.16M | 35.39M | 35.31M |
| Operating Income | -5.73M | -7.42M | -11.00M | -17.04M | -8.82M |
| Income Before Tax | -8.21M | -10.49M | -13.10M | -23.42M | -10.82M |
| Income Tax Expenses | -8.00K | 44.00K | 47.00K | 63.00K | -22.00K |
| Earnings from Continuing Operations | -8.20M | -10.53M | -13.15M | -23.48M | -10.80M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.20M | -10.53M | -13.15M | -23.48M | -10.80M |
| EBIT | -5.73M | -7.42M | -11.00M | -17.04M | -8.82M |
| EBITDA | -3.88M | -5.60M | -9.07M | -14.99M | -6.72M |
| EPS Basic | -0.17 | -0.21 | -0.27 | -0.48 | -0.22 |
| Normalized Basic EPS | -0.12 | -0.12 | -0.16 | -0.24 | -0.13 |
| EPS Diluted | -0.17 | -0.21 | -0.27 | -0.48 | -0.22 |
| Normalized Diluted EPS | -0.12 | -0.12 | -0.16 | -0.24 | -0.13 |
| Average Basic Shares Outstanding | 49.56M | 49.50M | 49.42M | 49.19M | 49.09M |
| Average Diluted Shares Outstanding | 49.56M | 49.50M | 49.42M | 49.19M | 49.09M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
